Manufacturers are reviving their serialization plans
The pioneering firms that installed serialization and track-and-trace systems are being joined by a fast follower crowd, but an industry-wide commitment is still in the future
Obama seeks to strengthen supply chain security, protect US intellectual property
But will anti-terrorism concerns trump commercial interests?
Specialty pharma contracting provider makes prior authorization paperwork easy
Armada Health Care streamlines prior auth with free ApproveRx service
HDMA updates its barcode guidance for wholesaler members
New guidelines prepare for eventual item-level serialization, while embodying FDA guidance for barcoded hospital-supply products
Verify Brand re-enters life-sciences serialization market with dedicated software offering
Company is bringing its expertise from outside life sciences
New York State considers real-time reporting of controlled-substances prescribing
Aim is to reduce ‘doctor shopping’ for prescriptions, and to better monitor patients and addicts’ health; potential system highlights data availability
UPS Healthcare Logistics adds to network with an Italian acquisition
Purchase of Pieffe Group, combined with new facility launches, brings UPS capacity nearly to 5 million sq.ft. worldwide; more expected in 2012
US wholesaler-distributor network saves manufacturers $42 billion annually, says HDMA research center
New edition of 'The Role of Distributors,' plus a new report on specialty pharmaceutical distribution, highlight distributors’ roles in healthcare
Gartner 2011 Healthcare Supply Chain Top 25 puts Cardinal Health at No. 1
Analysis combines financial and operational performance, and industry reputation, among manufacturers, distributors and healthcare systems
Digital marketing captures a greater 'share of mind' among pharma marketing, says Cutting Edge Information
Pharma companies are beginning to staff up internally—in part out of dissatisfaction with the capabilities of outside marketing agencies they employ
The shape of the home infusion industry
Home infusion association gathers member data, measuring variations in business practices
California biotech CEOs want: more money; less FDA regulation
Preview of annual PwC survey finds that disease foundations and NGOs are a growing part of biotech investment
IMS Health/SDI integration is essentially approved by FTC; Thomson Reuters reassesses divestiture
More reshuffling of healthcare-analytics market is in store
The global distribution perspective
Rapidly rising healthcare-products trade is almost being matched by increased regulatory scrutiny
Industry collaborates on logistics and supply chain security
With Rx-360 already at critical mass and delivering results, the call is out for more participation
Aggregate Spending Rules Arrive, But Industry Is Still Gearing Up
The 'Sunshine Act' provisions of the Affordable Care Act require records to be kept beginning Jan. 1
Battle lines draw up between PBMs and manufacturers who use copay coupons
PCMA study estimates additional $32 billion in added healthcare costs through 2021; coupons 'lure consumers to switch from generics to expensive brands'
The R&D Decline Is Worse Than Thought, Says Oliver Wyman
White paper points out the drop in pipeline performance; suggests a new direction is necessary
Brand Owner-CMO Collaboration Is Growing--But Is Far From Mature
The long-recommended practice of shared data and plans between biopharma companies and their contract manufacturing organizations (CMOs) is beginning to take hold
Understanding Class of Trade Concepts
‘Class of Trade’ is a murky element of contracts and channel analytics that can have important legal implications
Generics Manufacturers Grapple With Tight Economics
But the global picture is sunny as most of the global market growth benefits the generic makers
Recognizing Critical Gaps in Today's Supply Chain for Temperature-Sensitive Drugs
The potential of translational research for new medicines
The proposed federal National Center for Advancing Translational Sciences holds promise for drug development
FDA offers draft guidance on unsolicited requests for off-label drug information
The basic principle is: say as little as possible in public—and document what is said privately
FDA achieves part of its 'class wide' REMS for immediate-release fentanyl
Manufacturers will share a common access program
